REGN has been the topic of a number of other research reports. Leerink Swann reissued a positive rating and issued a $552.00 target price (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Piper Jaffray Companies reissued an overweight rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 10th. Guggenheim reissued a buy rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Jefferies Group LLC reissued a hold rating and issued a $500.00 target price (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Hold and an average price target of $488.57.
Regeneron Pharmaceuticals (REGN) traded down $5.17 during trading on Tuesday, hitting $397.45. The company had a trading volume of 1,446,334 shares, compared to its average volume of 849,075. The company has a market capitalization of $42.59 billion, a PE ratio of 37.35 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the firm posted $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. research analysts anticipate that Regeneron Pharmaceuticals will post 13.77 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “J P Morgan Chase & Co Reaffirms Hold Rating for Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/j-p-morgan-chase-co-reaffirms-hold-rating-for-regeneron-pharmaceuticals-inc-regn.html.
In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 89,468 shares of company stock valued at $42,312,448 in the last 90 days. 10.80% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in REGN. Janus Henderson Group PLC boosted its holdings in shares of Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after purchasing an additional 1,552,948 shares during the period. Jennison Associates LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after purchasing an additional 550,247 shares during the period. FMR LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares during the period. Old Mutual Global Investors UK Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 500,446.2% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after purchasing an additional 325,290 shares during the period. Finally, Clearbridge Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 55.2% in the 1st quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after purchasing an additional 245,531 shares during the period. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.